DaHui is experienced in advising on Chinese anti-monopoly and unfair competition law. We have advised on all aspects of anti-monopoly law (AML), unfair competition law and their implementing guidelines and regulations. We have extensive experience handling matters that implicate the Anti-monopoly Bureau at the Ministry of Commerce, the National Development and Reform Commission, the Ministry of Industry and Information Technology, the State Administration for Industry and Commerce and other relevant government and industry bodies. Our deep involvement in such matters allows us to remain at the cutting edge of developments in the field.
We have assisted a number of international companies to secure AML clearance for inbound mergers. We also advise on long-term AML compliance, designing compliance plans, structuring commercial transactions and holding training seminars for client companies.
Our services in this area include the following:
Advised well-known private equity firm Advent on carrying out China merger control procedures in relation to its acquisition of the methacrylates business of Evonik, one of the largest speciality chemicals companies in the world.
Represented BMW in the China merger control procedures for its acquisition of BMW Brilliance.
Advised The Coca Cola Company and China Mengniu Dairy Company, as the leading enterprises in their areas, on the China merger control procdures for establishing a PRC joint venture to produce a new chilled milk product.
Advised venerable CVC Capital Partners on China merger control procedures for its acquisitions of Bosch Packaging Technology GmbH (n.k.a. Syntegon) and DFE Pharma.
Advised Indorama Ventures, a world-leading producer in the intermediate petrochemicals industry, on the China merger control procedures in relation to its acquisition of DuPont Teijin Films (DTF), the world's premier producer of polyester films and related services, itself a joint venture of the United States' Dow DuPont and Japan's Teijin.